SGO in the News

SGO in the News

2017 Annual Meeting Media Coverage

The following articles are a sampling of the media coverage received by the 48th SGO Annual Meeting on Women’s Cancer held in National Harbor, MD, March 12-15, 2017.

The Hill: The HPV vaccine– it’s cancer prevention in the hands of physicians and parents

Healio: Society outlines plan to address ‘crisis’ in gynecologic cancer trial access

OncologyPractice.com: Maintenance taxane therapy of no benefit in advanced ovarian cancer

The ASCO POST: SGO 2017: New Immunotherapy Axalimogene Filoslisbac Shows Positive Results in Cervical Cancer

Pharma Intelligence: AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza

CancerConnect.com: Lynparza Improves Progression-Free Survival in BRCA-Mutated Ovarian Cancer

All Daily News: Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data

OncoTherapy Network: New Biomarker May Help Detect Metastatic Endometrial Cancer

PM 360: Experts warn against readmissions as sole quality measure in ovarian cancer

ACS Surgery News: Pain and impaired QOL persist after open endometrial cancer surgery

NASDAQ Globe Newswire: TESARO Announces Niraparib Data Presentations at the 2017 SGO Annual Meeting on Women’s Cancer

MedPage Today

More HPV Pathology with Single-Dose Vaccine

Survival Bump in IVB Cervical Cancer with Pelvic RT

CURE Today

PARP Inhibitors Are Changing the Treatment Landscape for Ovarian Cancer

Hormonal Maintenance Therapy Improves Progression-Free Survival in Ovarian Cancer

Cancer Network

Whole Pelvic Radiation May Improve Survival in Advanced Cervical Cancer

Chemotherapy Induces Molecular Changes in High-Grade Serous Ovarian Carcinoma

Maintenance Chemo After CR Fails to Extend Survival in Ovarian Cancer

Cancer Therapy Advisor

Cervical Cancer: SLN Biopsy Associated With Fewer Complications

Chemotherapy Fails To Prolong Survival in Low-grade Serous Ovarian Cancer

Adding Whole Pelvic Radiation to Chemotherapy May Prolong Survival in Advanced Cervical Cancer

BRCA1, RAD51C Methylation Linked to Response to PARP Inhibitors

Burnout and Productivity Loss Among Gynecologic Oncologists

Combined Liquid Pap and CT-DNA Testing May Detect Ovarian Cancer

Immunotherapy Motolimod Fails to Improve Survival in Ovarian Cancer

Patients With Ovarian Cancer Rank Nausea as Most Concerning Chemotherapy Side Effect

Adding Whole Pelvic Radiation to Chemotherapy May Prolong Survival in Advanced Cervical Cancer

 

Onclive

Dr. Barber on Surgical Readmission and Survival in Ovarian Cancer

New Screening Approach Effective in High-Risk Women Who Delay Oophorectomy

Dr. Swisher on Next Steps of Treatment for Ovarian Cancer

Dr. Annunziata on Olaparib and Cediranib Combination in Ovarian Cancer

Hormonal Maintenance Therapy Improves PFS in Low-Grade Serous Ovarian Cancer – See more at: D. Bucco OncLive

Refined Approach Required for Immunotherapy Success in Gynecologic Cancers

Niraparib Effective in Ovarian Cancer, Regardless of BRCA Status

Maintenance Olaparib Shows Impressive PFS Benefit for BRCA+ Ovarian Cancer

Gynecologic Oncologists Cite Time, Money as Barriers to Global Health Participation

MMR Deficiency Linked to PD-L1 Expression in Endometrial Cancer

 

Oncology Nurse Advisor

Priority Symptoms Identified in Recurrent Ovarian Cancer

Completing HPV Vaccine Doses Has No Added Protective Benefit

Rucaparib Active in Relapsed, Platinum-sensitive Ovarian Cancer

Perioperative Pain Control Reduces Need for Postoperative Narcotics After Hysterectomy for Uterine Cancer

Nonadherence to Guidelines, Low-Volume Centers Linked to Lower Cervical Cancer Survival

High Rates of Persistent Opioid Use 6 Months After RT for Cervical Cancer

Nonadherence to Guidelines, Low-Volume Centers Linked to Lower Cervical Cancer Survival

Completing HPV Vaccine Doses Has No Added Protective Benefit

Web-based Symptom Management Improves Symptom Controllability in Ovarian Cancer

Chemotherapy or VBT Improve Survival in Uterine Papillary Serous Carcinoma

HPV Vaccination Discussions Need to Focus on Education, Awareness

Targeted Oncology

Ovarian Cancer Study Explores Ideal Number of Neoadjuvant Chemotherapy Cycles

Analysis Gives New Insights Into Rucaparib Promise in Ovarian Cancer

Expert Explains the Importance of Genetic Testing for Patients With Ovarian Cancer

Rucaparib Promising Agent for Patients With Relapsed Ovarian Cancer

HPV-Targeting Therapy Tops Survival Mark in Metastatic Cervical Cancer

Expert Discusses Success Seen With Niraparib Maintenance Therapy for Ovarian Cancer

Niraparib Maintenance Results Have Paradigm-Shifting Potential in Ovarian Cancer, Expert Says

Big Increase in PFS With Maintenance Olaparib for BRCA+ Ovarian Cancer

Gene Expression Signature Predicts Outcomes in Endometrial Cancer

Immune Stimulant No Help When Added to Chemotherapy for Recurrent Ovarian Cancer

No Survival Benefit with Maintenance Chemotherapy in Ovarian Cancer

Carboplatin Desensitization Leads to Improved OS in Ovarian Cancer
SGO in the News Archives